News

Relative Bioavailability Trial of Nanotechnology-Enhanced Enzalutamide is Underway

January 10, 2024

Nanoform has completed the First Subject First Visit in a trial evaluating the relative bioavailability of its nanotechnology-enhanced enzalutamide.

Cherwell Joins AnalytiChem Group

January 10, 2024

Cherwell Laboratories’ cleanroom microbiology solutions will join AnalytiChem’s group of seven companies across Europe, North America, and Australia.

GSK to Acquire Aiolos Bio, Expands Respiratory Portfolio

January 09, 2024

In a deal worth up to $1.4 billion, GSK aims to acquire Aiolos Bio and gain an expanded pipeline of biologic-based respiratory therapeutic candidates.

Leiters Health Recalls Vancomycin IV Bags, Phenylephrine IV Bags, and Fentanyl IV Bags

January 09, 2024

The potential for superpotent drug initiated the voluntary recall.

WuXi AppTec Expands Peptide and API Manufacturing

January 09, 2024

The expansion will boost solid-phase peptide synthesis total reactor volume to 32,000 L.

DoD Grants Additional Funds to MediWound for Advancement of Non-Surgical Treatment for Field Care Burns

January 05, 2024

MediWound has been granted an additional $6.7 million by the DoD to advance NexoBrid as a non-surgical field care solution for the US military.

Boehringer Ingelheim and Ribo Partner on RNA-based Liver Disease Therapeutics

January 05, 2024

Under the collaboration, Boehringer Ingelheim and Ribo will develop RNA-based therapeutics to treat NASH/MASH.

Roche to Acquire Point-of-Care Technology from LumiraDx in $350 Million Deal

January 04, 2024

Roche will acquire select parts of the LumiraDx group related to that company’s point-of-care technology, which integrates multiple tests on a single instrument.

AstraZeneca Poised to Acquire Cell Therapy Developer, Gracell, in Deal Valued at $1.2 Billion

January 04, 2024

AstraZeneca’s acquisition of Gracell includes a clinical-stage autologous cell therapy targeting hematologic malignancies and autoimmune diseases and a proprietary manufacturing platform.

QurAlis Opens European Headquarters in The Netherlands

January 04, 2024

The new Europe headquarters will be the hub for the company’s European operations, including production of product.